SCCS OPINION on Genistein and Daidzein - SCCS/1641/22 Final version - Archive ouverte HAL Accéder directement au contenu
Ouvrages Année : 2022

SCCS OPINION on Genistein and Daidzein - SCCS/1641/22 Final version

U. Bernauer
  • Fonction : Auteur
Q. Chaudhry
  • Fonction : Auteur
P.J. Coenraad
  • Fonction : Auteur
M. Dusinska
  • Fonction : Auteur
J. Ezendam
  • Fonction : Auteur
C. L. Galli
  • Fonction : Auteur
B. Granum
  • Fonction : Auteur
E. Panteri
  • Fonction : Auteur
V. Rogiers
  • Fonction : Auteur
M. Stepnik
  • Fonction : Auteur
T. Vanhaecke
  • Fonction : Auteur
S. Wijnhoven
  • Fonction : Auteur
N. Cabaton
  • Fonction : Auteur
A. Koutsodimou
  • Fonction : Auteur
W. Uter
  • Fonction : Auteur
N. Von Goetz
  • Fonction : Auteur

Résumé

SCCS OPINION on Genistein and Daidzein - SCCS/1641/22 Final version U. Bernauer, L. Bodin, Q. Chaudhry, P.J. Coenraad, M. Dusinska, J. Ezendam, E. Gaffet, C. L. Galli, B. Granum, E. Panteri, V. Rogiers, Ch. Rousselle, M. Stepnik, T. Vanhaecke, S. Wijnhoven, N. Cabaton, A. Koutsodimou, W. Uter, N. von Goetz The SCCS adopted this document by written procedure on 16 September 2022 (153 pages) Mise en ligne 23 Septembre 2022 https://health.ec.europa.eu/publications/genistein-and-daidzein_en Details Publication date : 23 September 2022 Author : Scientific Committee on Consumer Safety (SCCS) Description SCCS members: U. Bernauer (Rapporteur Daidzein), L. Bodin, Q. Chaudhry (Rapporteur Genistein), P.J. Coenraads (Chairperson), M. Dusinska, J. Ezendam, E. Gaffet, C.L. Galli (Rapporteur Genistein), B. Granum (former member), E. Panteri, V. Rogiers, Ch. Rousselle (Rapporteur Daidzein), M. Stepnik, T. Vanhaecke, S. Wijnhoven SCCS external experts: N. Cabaton, A. Koutsodimou, W. Uter, N. von Goetz Contact:SANTE-SCCS@ec.europa.eu On request from: European Commission SCCS Number: SCCS/1641/22 Adopted on: 16 September 2022 Conclusion of the opinion: (1) In light of the data provided and taking under consideration the concerns related to potential endocrine disrupting properties of phytoestrogens, (a) does the SCCS consider genistein safe when used in cosmetic products up to a maximum concentration of 0.007%? (b) does the SCCS consider daidzein safe when used in cosmetic products up to a maximum concentration of 0.02%? From the safety assessment based on the available relevant data on the aglycone form of genistein and daidzein, and in consideration of the potential endocrine disrupting properties of phytoestrogens, the SCCS considers that: a) the use of genistein (CAS No 446-72-0, EC No 207-174-9) in cosmetic products up to a maximum concentration of 0.007% is safe. b) the use of daidzein (CAS No 486-66-8, EC No 207-635-4) in cosmetic products up to a maximum concentration of 0.02% is safe. (2) Alternatively, according to the SCCS what is the maximum concentration of genistein and daidzein that is considered safe for individual and combined use in cosmetic products? / (3) Does the SCCS have any further scientific concerns with regard to the use of genistein and daidzein or other related phytoestrogens in cosmetic products? / Keywords: SCCS, scientific opinion, genistein (CAS No 446-72-0, EC No 207-174-9), daidzein (CAS No 486-66-8, EC No 207-635-4), Regulation 1223/2009 Opinion to be cited as: SCCS (Scientific Committee on Consumer Safety), Scientific opinion on genistein and daidzein, preliminary version of 12 January 2022, final version of 16 September 2022, SCCS/1641/22.
Fichier non déposé

Dates et versions

hal-03784690 , version 1 (23-09-2022)

Identifiants

  • HAL Id : hal-03784690 , version 1

Citer

U. Bernauer, L. Bodin, Q. Chaudhry, P.J. Coenraad, M. Dusinska, et al.. SCCS OPINION on Genistein and Daidzein - SCCS/1641/22 Final version. Scientific Committee for Consumer Safety (SCCS, EC). , 2022, Scientific Committee for Consumer Safety (SCCS, EC). ⟨hal-03784690⟩
22 Consultations
0 Téléchargements

Partager

Gmail Facebook X LinkedIn More